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Glossary 
APM   Antigen processing machinery 
β2m   Beta-2-microglobulin 
CAR   Chimeric antigen receptor 
CD3-ζ   Cluster of differentiation 3-zeta 
CSPG4  Chondroitin sulfate proteoglycan 4 
CTL   Cytotoxic T lymphocyte 
CTLA4  Cytotoxic T lymphocyte antigen 4 
DAB+   3,3’-Diaminobenzidine (chromogen) 
ER   Endoplasmic reticulum 
H&E   Hematoxylin & eosin 
HC-10   anti-HLA-B/C monoclonal antibody 
HC-A2  anti-HLA-A monoclonal antibody 
HLA   Human leukocyte antigen 
HMW-MAA  High molecular weight-melanoma associated antigen 
HRP   Horseradish peroxidase 
IFN-γ   Interferon-gamma 
IHC   Immunohistochemistry 
IL-2   Interleukin-2 
MGH   Massachusetts General Hospital  
MHC   Major histocompatibility complex 
NAMB-1  anti-beta-2-microglobulin monoclonal antibody 
NK   Natural killer (cell) 
PAS   Periodic acid-Schiff stain 
PD-1   Programmed cell death protein 1 
PD-L1   Programmed cell death protein ligand 1 
PDGFR-β  Platelet-derived growth factor receptor-beta 
TA   Tumor antigen 
TAP   Transporter associated with antigen processing 
TBST   Tris buffered saline with Tween 20 (solution) 
TCR   T cell receptor 
TNF   Tumor necrosis factor 
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Abstract 
Recent advances in immunotherapy for cancer have led to increasing interest in the role 
of the immune system in the pathogenesis and treatment of various tumors. Tumor-infiltrating 
lymphocytes have been associated with more favorable prognoses in a number of malignancies, 
though the mechanism of such outcomes remains unclear. This study, to our knowledge, is the 
first to describe lymphocytic infiltration in chordoma. Hematoxylin and eosin stained slides from 
62 randomly selected patients with chordoma treated at MGH were evaluated for lymphocyte 
infiltrates. Lymphocytic infiltration was found in 84% of tumors, with lymphocytes primarily 
distributed in the fibrous septae surrounding the physaliferous cells. Twenty-four tumors were 
randomly selected for immunohistochemical (IHC) analysis. All of the tumors with lymphocytic 
infiltration that underwent IHC staining had CD4-positive lymphocytes present, ranging from 1-
300 cells per high-power field. CD8-positive lymphocytes were noted in 52% of tumors, ranging 
from 1-39 cells per high-power field. HLA class I antigen defects were noted in 79% of 
chordoma tumors. These included negative membranous and/or cytoplasmic staining patterns, 
weakly positive staining, and heterogeneous combinations of these defects in variable 
percentages of chordoma cells. Both heavy chain isoforms and beta-2-microglobulin components 
were affected. Our novel finding of intratumoral lymphocytes in chordoma tumors suggests that 
a patient’s immune system mounts a response against his/her tumor. The absence of HLA class I 
antigen components is compatible with the possibility that a patient’s immune response imposes 
selective pressure that facilitates the outgrowth of chordoma cell subpopulations that have 
developed escape mechanisms from host immune recognition. We are the first to report these 
original findings in chordoma, and while the clinical significance requires further evaluation, 
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these data have implications in optimally selecting patients for appropriate treatment regimens. 
We believe these data will spark further inquiry into the role of immunotherapy in the treatment 
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Introduction 
The Role of the Immune System in Cancer 
The interaction between the immune system and malignancy has long been studied. The 
immune system plays a critical role in eliminating abnormal cells (1). These abnormal cells 
harbor molecular signatures that are recognized as non-self antigens by immune cells that are 
constantly surveying the cells in our body. When an immune cell, such as a cytotoxic T 
lymphocyte (CTL), encounters a non-self antigen, it engages in a process that leads to cell death 
for the abnormal or intruder cell. As will be described below, tumor antigens (TA) are processed 
by malignant cells and are displayed on the tumor cell surface via the human leukocyte antigen 
(HLA) class I antigen complex. Studies have shown that these TA are viewed as non-self 
antigens by circulating immune cells, leading to tumor cell destruction as a result of interactions 
with the immune system. These interactions, and mechanisms that allow tumors to specifically 
evade such interactions, which will be further described in the following sections, are what 
inspired this research program and led to the work performed in this thesis. 
 
The HLA Class I Antigen Complex and Tumor Antigen Processing 
The HLA system is the human analog of the major histocompatibility complex (MHC), a 
group of genes on chromosome 6 that encode cell surface markers and antigen processing 
machinery (APM) involved in the innate and adaptive immune responses, as well as in infection, 
autoimmunity, and malignancies (2). The HLA class I region contains genes that encode both 
classical and non-classical class I antigens. For the purposes of this brief introduction, only the 
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classical antigens will be discussed, as they are the standard molecules involved in antigen 
presentation and the immune interactions that will be detailed below.  
The classical HLA class I antigens, HLA-A, HLA-B, and HLA-C, are normally 
expressed on all human cell types, with the exception of erythrocytes and trophoblasts (1). The 
complete HLA class I antigen is a dimer composed of a transmembrane heavy (alpha) chain and 
an associated light (beta) chain, beta-2-microglobulin (β2m). The β2m component is non-
polymorphic and is encoded on chromosome 15, which is not part of the MHC.  
One of the major roles of the HLA in human cells is to process endogenous proteins 
intracellularly and present short amino acid sequences on the cell surface via the HLA class I 
antigen complex (1). In malignant cells, these unfamiliar tumor antigens are exhibited on the cell 
surface, allowing for recognition by cognate T lymphocytes (3) (Fig. 1). Primed T cells 
recognize TA presented by the HLA class I antigen via interaction with the T cell receptor 
(TCR). This interaction leads to a cytotoxic effect that leads to tumor cell destruction. 
Antigen processing begins with the synthesis of the heavy chain and β2m components in 
the endoplasmic reticulum (ER) (1). These components associate with the chaperone proteins 
calnexin, calreticulin, and Erp57, which stabilize the heavy and beta chains and prevent loading 
of self-peptides from the ER itself. The heavy and beta chains then associate with the amino acid 
transporter TAP, which is stabilized by the chaperone protein tapasin. In the cytosol, proteins to 
be degraded are ubiquitinated and thereby directed towards the proteasome. In the context of 
immune activation or inflammation, IFN-γ induced expression of LMP-2 and LMP-7 leads to 
proteasome augmentation with these new subunits. This augmented proteasome creates peptides 
of optimal length for HLA class I presentation, approximately 8-10 amino acids long. TAP then 
transports these short peptides from the cytosol into the ER, where they associate with the heavy 
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and beta chains, stabilizing the complex. This peptide-HLA antigen complex is then transported 
to the cell surface for antigen presentation. An intact HLA class I antigen complex is needed in 
order to present TA on the tumor cell surface for possible interaction with a TCR on specifically 
primed CTLs. 	  
Immune Escape Mechanisms in Cancer 
A growing body of evidence indicates that a major obstacle to the success of 
immunotherapy is represented by the many escape mechanisms utilized by tumor cells to avoid 
recognition and destruction by the host’s immune system (4). Among them are defects in the 
HLA class I antigen. Many malignancies have been shown to have absent or mutated expression 
of HLA class I antigen components, as studied and reviewed extensively by our lab (4-16). To 
our knowledge, this is the first study to examine HLA class I expression in human chordomas 
and to report similar defects in these tumors. 
These immune escape mechanisms are clinically significant in malignancies due to their 
role in the pathogenesis of tumors (4). If a malignant cell is able to evade immune cell detection, 
it has the ability to grow and divide unchecked in the tumor microenvironment, leading to 
increased tumor burden in patients, as well as a more aggressive tumor phenotype. The 
significance of these HLA class I antigen defects in cancer is underscored by the interaction 
between immune cells and malignant cells.  
One school of thought is that tumor-infiltrating lymphocytes exert an immune response 
against the patient’s tumor. The presence of tumor-infiltrating lymphocytes has been associated 
with improved prognoses in numerous malignancies, including melanoma (17-20), breast cancer 
(21-24), lung cancer (25-29), colorectal cancers (30-51), and ovarian cancer (52-54). Data from 
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large clinical studies demonstrate that a robust infiltration of neoplastic lesions by specific 
immune cell populations, including, but not limited to, CD8+ cytotoxic T lymphocytes (CTL), 
Th1 and Th17 CD4+ T cells, natural killer (NK) cells, dendritic cells, and M1 macrophages 
constitutes an independent favorable prognostic indicator in several types of cancer (55). The 
mechanism by which this effect occurs is currently unknown, however more recently, increasing 
attention has been paid to the role of immunosurveillance in the pathogenesis and clinical course 
of cancer, with particular emphasis on the application of immunotherapy for treatment (56). The 
aforementioned studies suggest that the immune system plays a dynamic role in regulating 
tumors. The immune cell-malignant cell interaction is important in not only preventing 
malignant cells from colony formation, but also in keeping clonal expansion at bay. Thus, the 
immune system plays a role in controlling tumor progression even if it has failed in preventing 
tumor formation. This has led to renewed interest in understanding the mechanisms that drive 
these processes, as well as developing strategies to stimulate the immune system as a way to treat 
cancer. 
 
Immunotherapeutic Strategies for the Treatment of Cancers 
For decades now, researchers have understood the importance of utilizing 
immunotherapy in the treatment of cancers. However, until recently, aside from the successful 
use of monoclonal antibodies in certain types of cancers, we have been limited in the number of 
immune-mediated pathways we could utilize to treat tumors. In the past few years, significant 
progress has been made in bringing immunotherapeutic strategies back to the forefront of cancer 
management, and these have garnered considerable attention (57, 58).  
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Highlighting these successes are the recent studies describing the use of immune 
checkpoint blockade in treating various malignancies (57). The immune checkpoint molecules 
these therapies target are the programmed cell death protein 1 (PD-1) and the cytotoxic T 
lymphocyte antigen 4 (CTLA4). The binding of PD-1 on T cells with its ligands, PD-L1 and PD-
L2, on tumor cells initiates an inhibitory effect that negatively regulates TCR signaling and leads 
to apoptosis of T cells (59). Nivolumab and pembrolizumab are examples of monoclonal 
antibodies directed against PD-1 (60-62). By blocking the interaction of PD-1 with its ligands, 
these antibodies prevent T cell exhaustion and death, and thereby boost the immune response 
specifically targeted against tumors. CTLA4 is expressed on helper T cells and has a similar 
structure to CD28. While CD28 is a costimulatory molecule that binds to the B7 family of 
molecules on antigen presenting cells and enhances the immune response, CTLA4 is its 
antagonist and initiates a cascade of inhibitory signaling that ultimately serves as an “off” switch 
for T cell-based immune attack (63). As another example of a negative regulator of the immune 
response, CTLA4 was identified as a target for blockade, and ipilimumab, a CTLA4-specific 
monoclonal antibody, was the first example of FDA-approved immune checkpoint blockade 
therapy for cancer (64).  
Another immunotherapeutic strategy recently garnering significant interest is the use of 
chimeric antigen receptors (CARs), or artificially engineered TCRs specific to a tumor antigen. 
Briefly, CARs are fusions of single-chain variable fragments from monoclonal antibodies with 
the intracytoplasmic and transmembrane domains of the CD3-ζ molecule. In a process known as 
adoptive cell transfer, T cells are isolated from a patient and CTLs are modified to express the 
TA-specific CAR via viral vector transduction. The result is CAR-modified T cells with TCRs 
that are unique and specific to the tumor cells they intend to target, leading to tumor cell 
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destruction when reintroduced into the patients (65). Early pre-clinical and phase I clinical 
studies utilizing adoptive cell transfer of CAR-modified T cells in various malignancies show 
promise that this strategy could soon become another option in cancer therapy (66).  
A final strategy that might soon offer another opportunity to take advantage of the 
interaction of the immune system and cancer is the advent of successful tumor antigen 
vaccination. Patients with tumors known to overexpress a certain antigen can be vaccinated with 
low-dose inactivated antigen in order to drive an antigen-specific T cell response. While these 
vaccines have been notoriously difficult to create and have historically yielded only modest 
effect in early clinical trials, newer vaccines are showing early signs of success. For example, 
preliminary results from an open-label phase I clinical trial vaccinating chordoma patients with 
heat-killed recombinant yeast modified to express the brachyury protein suggest that certain 
patients have an immune response to brachyury (67). While these initial results only represent a 
small cohort of seven chordoma patients, the study showed that patients who were vaccinated 
with this yeast-brachyury vaccine were able to mount both CD4 and CD8 responses with 
increased intracellular expression of pro-inflammatory and immune stimulating cytokines IFN-γ, 
TNF, and IL-2, as well as the perforin and granzyme marker CD107a. 
 
Chordoma 	   Chordoma is a primary malignancy of the axial skeleton originating from notochordal 
remnants (68). The embryologic notochord gives rise to the nucleus pulposus of intervertebral 
discs, which undergo malignant transformation to become chordoma. These rare tumors have an 
annual incidence of approximately 1 per 1 million people, and they tend to be locally aggressive 
and have a high rate of recurrence. Anatomically, they are primarily found in the sacrococcygeal 
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region and also often at the skull base involving the clivus (69). Pathologically, gross specimen 
are gelatinous pinkish-gray masses with solid and cystic components. Low-power microscopic 
examination reveals lobules of epithelioid cells encompassed in clusters by surrounding fibrous 
septae in a background of mucinous matrix. The pathognomonic cell type for chordoma is the 
physaliferous cell, which has a heavily vacuolated cytoplasm. Chordoma is 
immunohistochemically identified by strongly positive cytokeratin and brachyury expression, as 
well as weak positivity for PAS and S-100. Brachyury is a transcription factor involved in 
notochordal development and is overexpressed in chordoma (70).  
 The standard of care for chordoma is en bloc resection, with the goal of negative margins, 
and adjuvant radiation therapy (68). Unfortunately, this treatment paradigm has not drastically 
shifted over the past few decades, and chordoma remains a cancer ridden with significant 
morbidity and mortality. Effective first-line small molecule-based targeted therapy does not exist 
for chordoma. Rare cases of advanced PDGFR-β-positive chordomas treated with imatinib have 
shown a modest survival benefit and halting of disease progression, suggesting that imatinib may 
have some antitumor activity in chordoma (71). Imatinib has also been used as off-label salvage 
therapy in patients with disease refractory to conventional treatment. Chemotherapy has proven 
to be largely ineffective (72). Radiation therapy for chordoma has been shown to provide both 
therapeutic and palliative benefit in patients. While most centers provide adjuvant radiation, 
MGH has published a phase II clinical trial describing improved local control for chordomas 
receiving both neoadjuvant and adjuvant proton beam radiation therapy (73). Ultimately, the lack 
of curative options for chordoma led us to think about other strategies we could use to try to 
devise new ways to treat this disease.  
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Rationale and Significance 
Incidental observations of dense lymphocytic infiltrates in resected human chordoma 
specimens by our research group, paired with the prospect of the increasing clinical relevance of 
these findings, led us to develop our research program described here. While immune cell 
infiltrates have been noted in a number of tumors, no such reports for chordoma existed prior to 
this study. Additionally, we sought to investigate the role of these intratumoral lymphocytes in 
the pathogenesis of chordoma, with specific focus on potential implications for immunotherapy. 
Knowledge of defects in HLA class I antigen components in chordoma provides insight into the 
possible mechanism(s) of immune escape in this tumor, and also aids in the development and 
application of appropriate immunotherapy as well as optimal selection of patients for certain 
treatment paradigms. The work performed in this thesis has potential future implications in 
chordoma therapy. 
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Materials and Methods 
Patients with chordoma treated as the Massachusetts General Hospital (MGH) between 
1989-2009 were identified and selected from the Orthopaedic Oncology database with approval 
from the MGH institutional review board. All slides were reviewed in tandem with a senior bone 
and soft tissue pathologist in order to confirm the diagnosis of chordoma and to ensure that 
sufficient tumor material was present on each slide.   
Lymphocytic Infiltration 
 Hematoxylin and eosin (H&E) stained human chordoma tissue slides from 62 randomly 
selected patients were assessed for lymphocyte presence and histologic location. A total of 387 
slides (average of 6 slides per patient, range 2-19, SD 3.1) were assessed in order to ensure 
adequate tumor specimens were reviewed at multiple levels within the tumor for lymphocytic 
infiltration and localization.  
Immunohistochemical Staining 
 Formalin-fixed paraffin-embedded human chordoma tissue samples from 24 tumors were 
randomly selected. Four-micron thick tissue sections were deparaffinized and subjected to 
antigen retrieval. Slides with incubated in 3% hydrogen peroxide for 20 minutes and then rinsed 
in TBST. Following incubation with blocking buffer, slides were incubated with anti-HLA-A 
(HC-A2, (74)), -HLA-B/C (HC-10, (75)), -beta-2-microglobulin (NAMB-1, (75)), -CD4 (Dako), 
-CD8 (Dako) monoclonal antibodies overnight at 4°C. After rinsing with TBST, slides were 
incubated for 45 minutes at room temperature with EnVision™+ Dual Link System-HRP goat 
anti-mouse immunoglobulin (Dako). Antibody binding was detected with the DAB+ Peroxidase 
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Substrate Kit (Dako), and the slides were counterstained with hematoxylin. Slides were then 
dehydrated and mounted with coverslips.  
 Staining results were analyzed by at least two investigators in combination with a senior 
bone and soft-tissue pathologist. Slides were examined throughout the tissue section at high-
power (200X) magnification. For HLA class I expression in chordoma cells, both staining 
intensity and percentage of tumor cells staining positive were assessed. Staining intensity was 
scored 0 (negative), 1+ (weakly positive), or 2+ (strongly positive). Both cytoplasmic and 
membranous staining were considered positive for HLA-A, HLA-B/C, and beta-2-microglobulin 
staining. For CD4 and CD8 staining of lymphocytes, four high-power fields were randomly 
chosen on slides and the number of positively staining lymphocytes were counted. Membranous 
staining was considered positive for CD4 and CD8 staining. 	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Results 
Lymphocytic Infiltration in Chordoma 
Lymphocytic infiltration was found in 52 (84%) of the tumors removed from 62 patients. 
The presence or absence of lymphocytes was homogeneous in 45 (73%) tumors; 35 were 
positive and 10 were negative. In the remaining 17 (27%) tumors, the presence of lymphocytes 
was heterogeneous, with areas of lymphocyte infiltrate associated with areas with no detectable 
lymphocytes. The lymphocyte infiltrates were distributed in two distinct patterns; either 
primarily in the fibrous septae of tumor lobules or between the physaliferous cells within tumor 
lobules (Fig. 2).  
Consistent with our findings above, 88% of the 24 tumors that underwent 
immunohistochemical analysis exhibited lymphocytic infiltration. Of those with lymphocytic 
infiltrates, 19% had lymphocytes distributed between chordoma cells within the tumor lobules. 
All but one of the tumors with lymphocytic infiltration had lymphocytes located within the 
fibrous septae of chordoma lobules. All 21 tumors with lymphocyte infiltrates had CD4-positive 
lymphocytes present (Fig. 3). The number of CD4-positive lymphocytes per high-power field 
was not uniform in the chordoma tumors, ranging from 1-300 lymphocytes per high-power field. 
Fifty-two percent of the tumors with lymphocytic infiltration had CD8-positive lymphocytes 
present. Like the CD4-positive lymphocytes, the number of CD8-positive lymphocytes was not 
uniform in the chordoma tumors, and ranged from 1-39 per high-power field. 
HLA Class I Antigen Defects in Chordoma 
 Of the 24 tumors tested, 29% were completely negative for HLA-A heavy chain staining 
(Fig. 4, Fig. 5). Thirty-three percent of tumors had less than 60% of chordoma cells stain 
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positively for the HLA-A heavy chain. Of these, 25% were weakly positive and another 25% 
were strongly positive but only stained rare chordoma cells (less than 10% of the tumor). 
 For the HLA-B/C heavy chain isoform, 17% of tumors tested were completely negative, 
and an additional 46% of tumors had less than 50% of chordoma cells stain positively for this 
HLA class I antigen component. Of these 11 tumors with decreased cytoplasmic and 
membranous staining of chordoma cells, 36% stained only rare chordoma cells (less than 10% of 
the tumor) and 36% were weakly positive. 
 While no tumors were completely negative for the beta-2-microglobulin component, 17% 
exhibited positive staining of less than 60% of chordoma cells and 46% of tumors were only 
weakly positive.  
In total, 19/24 (79%) of the tumors tested exhibited a defect in at least one of the 
components of the HLA class I antigen. No tumors were pan-negative. All component-specific 
monoclonal antibodies resulted in staining patterns ranging the full spectrum from completely 
negative to strongly positive staining of various percentages of chordoma cells.  
	   17	  
Discussion 
 Tumor-infiltrating lymphocytes have been shown to portend an improved prognosis in 
patients with a number of malignancies (18, 23, 25, 28, 33, 35, 38, 40-42, 44, 45, 48, 49, 52, 53, 
55). Our results are the first to describe and characterize lymphocytic infiltration in human 
chordoma tumors. Our data suggests that these lymphocytes represent an immune response by 
the host patient mounted against his/her tumor. The result of this interaction is likely manifested 
in the absent or decreased expression of HLA class I antigen components in tumor cells. This is 
consistent with the possibility that these intratumoral lymphocytes impose selective pressure on 
the physaliferous cells, which leads to the outgrowth of specific malignant cell subpopulations 
that have developed mutations that allow for escape from immunosurveillance. Our study, which 
is the first to describe lymphocytic infiltration and HLA class I antigen defects in chordoma 
tumors, contributes to an early mechanistic understanding of the interaction between the host 
immune system and the pathogenesis of chordoma in patients. This knowledge has implications 
in better understanding the role the immune system plays in regulating chordomas, classifying 
and prognosticating patient outcomes on the basis of their tumor and lymphocytic phenotype, 
and optimally selecting patients for appropriate therapy, whether that be through 
immunomodulation or other strategies.  
The results of recent clinical trials and the FDA approval of monoclonal antibodies 
specific to immune checkpoint molecules such as cytotoxic T lymphocyte antigen 4 (CTLA4) 
and programmed cell death protein 1 (PD-1) in various types of malignancies have rekindled 
interest in the role of immune surveillance in oncology and in the application of immunotherapy 
for the treatment of malignant diseases (60, 61, 76-89). An increasing number of recent studies 
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suggest that the CTLA4 and PD-1 pathways are utilized by tumor cells to evade immune cell-
mediated destruction (57). These pathways represent mechanisms for negative regulation of the 
T cell priming and effector phases, respectively, serving as a stopgap for unchecked immune 
responses and thus allowing tumors to escape T cell interactions (77). Immunotherapy focused 
on checkpoint blockade interferes with these negative regulators of T cells in order to drive an 
antitumor immune response. Tumeh et al. found that patients with higher numbers of CD8+, PD-
1+, and PD-L1+ cells in metastatic melanoma tumors responded more favorably to treatment with 
pembrolizumab, a humanized monoclonal antibody directed against PD-1 (62). Thus, our 
findings of high rates of lymphocytic infiltration in chordoma tumors, as well as subtype analysis 
showing significant CD4+ and CD8+ infiltrates, is consistent with the possibility that lymphocytic 
infiltration could serve as a predictor of prognosis for patients.  
Based on our proposed connection between intratumoral lymphocytes in chordoma and 
HLA class I antigen defects in the physaliferous cells, we postulate that the clinical behavior and 
phenotype of patients’ tumors can be identified and used as a biomarker for the activity of 
immunotherapeutic agents against the tumor. In patients with an intact HLA class I antigen 
complex, many immunotherapeutic strategies are potential options. For example, checkpoint 
blockade therapies, such as the monoclonal antibodies directed against PD-1 and CTLA4 
mentioned above, CAR-based T cell therapy, and tumor antigen vaccines could be utilized to 
treat patients. However, in patients with defects in HLA class I antigen components, many 
immunotherapy options are not possible. In this subset of patients, an argument can be made for 
more aggressive treatment paradigms, such as en bloc surgical resection with neoadjuvant and 
adjuvant proton radiation therapy. This therapeutic modality has been shown in a phase II 
clinical trial to provide effective local control which is durable for at least five years (73). With 
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the advent of newer CAR-based immunotherapies, tumors with defects in HLA class I antigen 
processing and presentation may still be able to be targeted by T cells if tumor-specific cell 
surface molecules are identified. The HLA class I antigen complex is utilized to present normally 
intracellular tumor antigen peptides on the cell surface for immune surveillance by T cells. 
However, molecules that are routinely transported to the cell surface by the ER-Golgi apparatus 
do not require intact HLA machinery. With adoptive cell transfer utilizing CARs, a patient’s T 
cells can be engineered artificially to recognize specific tumor cell surface markers, and can then 
be reintroduced into the patient for cytotoxic effect. A novel example of this strategy that our lab 
is currently working on in chordoma using CAR-modified T cells directed against the 
chondroitin sulfate proteoglycan 4 (CSPG4) is detailed below in the “Suggestions for Future 
Work” section. 
We hope these data will stimulate further studies investigating the efficacy of 
immunotherapeutics in malignancies, specifically chordoma, and their mechanism of action. 
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Conclusions 	   We are the first to describe and characterize lymphocytic infiltration in chordoma. 
Lymphocytic infiltration was noted in 84% of tumors, with distributions primarily in the fibrous 
septae of tumor lobules, but also amongst physaliferous cells. In tumors that underwent IHC 
analysis, the rate of lymphocytic infiltration was comparable. All tumors with lymphocytic 
infiltration had CD4 T cells present, and 52% of tumors with intratumoral lymphocytes had CD8 
T cells present. In total, 79% of the tumors examined displayed defective expression of at least 
one component of the HLA class I antigen. These defects of HLA class I heavy chain (HLA-A or 
HLA-B/C) or light chain (β2m) expression ranged from completely absent expression to varying 
combinations of weakly positive staining or a low percentage of tumor cells staining positive. No 
tumors were negative for all HLA class I antigen components and each monoclonal antibody 
used exhibited the full range of staining patterns, suggesting our data is robust and not a result of 
tissue artifact or sample preparation. We conclude that the high rate of lymphocytic infiltration in 
chordoma tumors is likely a result of the patient’s immune system mounting a response against 
their tumor. These data suggest that host immune cells apply selective pressure on physaliferous 
cells, leading to the outgrowth of malignant cell populations that have developed defects in the 
HLA class I antigen. These defects represent a mechanism of immune escape by chordoma 
tumors, and is important in understanding the pathogenesis of the disease and is paramount in 
understanding how to develop and apply immunotherapeutic strategies to the right patients based 
on individual tumor phenotypes.  
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Suggestions for Future Work 	   The work presented in this thesis represents the early stages of understanding the role of 
the immune system in chordoma progression and treatment. Before applying immunotherapeutic 
strategies to patients, a mechanistic understanding of how the host immune system interacts with 
the tumor and how tumors attempt to escape immune attack is necessary. Our novel findings of 
lymphocytic infiltration in chordoma and HLA class I antigen defects in physaliferous cells are 
the building blocks for further investigation into the immune-mediated pathogenesis of 
chordoma and potential for immunotherapy. We plan to further explore the interaction between 
chordoma and a patient’s immune system with the work outlined below, and we hope that this 
research program and our early, novel findings will stimulate future work in this field to help 
promote the development of new immunotherapeutic strategies for chordoma patients.  
 
Expression of HLA Class I Antigen Processing Machinery Components in Chordoma 	   Tumor antigen presentation requires intracellular tumor peptide processing, as described 
in the Introduction. While defects in the HLA class I antigen heavy and beta chains has 
implications at the tumor cell surface, improper or incomplete TA processing in the cytosol and 
ER can also lead to immune escape. Issues with TA processing will affect TA peptide loading, 
and will therefore prevent T cell recognition of tumor cells.  
 Our lab has created a unique panel of monoclonal antibodies directed towards APM 
components, including tapasin, TAP1, TAP2, calreticulin, calnexin, LMP-2, LMP-7, and Erp57. 
Some of these APM component-specific antibodies are not available commercially. IHC 
experiments examining human chordoma tissue sections for defects in HLA class I APM 
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components would be informative in assessing the full spectrum of this mechanism of immune 
escape utilized by chordoma. We have begun preliminary validation experiments using these 
monoclonal antibodies, and plan on reporting these results in a subsequent manuscript.  
 
Expression of Immune Checkpoint Molecules in Chordoma 
 Clinical trials utilizing monoclonal antibodies directed against the immune checkpoint 
molecules PD-1 and CTLA4 have been successful in a variety of tumors, as previously 
described. Given that we have identified lymphocytic infiltration in chordoma with both CD4 
and CD8 T cells, it is possible that PD-1/PD-L1/PD-L2 and CTLA4/B7 interactions play a role 
in chordoma as well. IHC analysis of human chordoma tissue sections for expression of these 
molecules could provide insight into the possible use of these immune checkpoint blockade 
therapies in chordoma patients. There are both commercially available and proprietary 
monoclonal antibodies that could be used to characterize expression of these molecules. PD-L1 
expression has recently been noted in osteosarcoma, another primary malignant bone tumor (90). 
However, to date, no one has reported expression of PD-L1/PD-L2 in human chordoma. 
   
Use of Chordoma-Specific CARs to Modify T cells Against Chordoma Cell Lines 
 Chimeric antigen receptors, as previously described, provide a novel opportunity to 
genetically engineer T cells with TCRs specific to TAs. Chondroitin sulfate proteoglycan 4 
(CSPG4), also known as high molecular weight-melanoma associated antigen (HMW-MAA), is 
a cell surface molecule involved in multiple signaling pathways important for tumor cell growth, 
survival, migration, and metastasis (91). A study from our group has shown that chordomas 
overexpress CSPG4 (92). Our collaborators, utilizing anti-CSPG4 monoclonal antibodies 
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generated in our laboratory, have very recently designed and validated second-generation CARs 
with specificity for CSPG4 (93). Our lab has also been able to successfully culture and expand 
human chordoma cell lines, namely UCH-1, in order to perform in vitro studies using human 
cells. 
We received the anti-CSPG4 CAR from our collaborator and are planning to use 
retroviral vector transduction of the CAR into peripheral blood T lymphocytes in order to 
generate anti-CSPG4 CAR-modified T cells. Analysis of cytolysis after co-culturing these CAR-
modified T cells with chordoma cell lines would provide insight into the efficacy of anti-CSPG4 
immunotherapy, specifically CAR-based strategies, in the treatment of human chordoma. If 
successful, these in vitro results could lead to the use of anti-CSPG4 CAR-modified T cells in 
vivo animal studies, and ultimately adoptive cell transfer phase I clinical trials in human patients 
with chordoma. 
 
Effect of Radiation on HLA Class I Antigen and APM Component Expression in 
Chordoma 	   Experiments performed in vitro and in animal models in collaboration with researchers at 
the National Cancer Institute have shown that low-dose irradiation can upregulate HLA class I 
APM component expression and can enhance the cell surface expression of calreticulin (94). 
These phenotypic changes increase the immunogenicity of tumor cells and their recognition by 
cognate T cells. 
 In light of these new findings, it is possible that radiation therapy could serve multiple 
roles in the treatment of chordoma. While radiation therapy is part of the standard of care 
clinically, it may also provide immunogenic modulation of tumors that enhance antigen 
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processing and presentation, allowing for improved T cell effect. At the Stephan L. Harris Center 
for Chordoma Care at MGH, en bloc surgical resection with neoadjuvant and adjuvant proton 
beam radiation therapy has been shown in a phase II clinical trial to provide durable local control 
(73). As a result of this treatment modality, we are in a unique position to study the effects of 
radiation on HLA class I antigen and APM component expression. Patients treated at MGH often 
have pre-radiation tissue biopsies performed in order to confirm the diagnosis of chordoma prior 
to initiating treatment. Thus, we have access to pre- and post-radiation chordoma samples from 
individual patients. IHC experiments using the monoclonal antibodies utilized in this thesis, as 
well as the ones directed against APM components we are validating (as noted above), can 
elucidate if radiation increases the immunogenicity of chordoma tumors. This would further 
justify more widespread and aggressive use of radiation in the treatment of chordoma patients.   
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Summary 	   Immunotherapy for cancer has recently garnered significant interest due to the successes 
of clinical trials utilizing immune checkpoint blockade therapy in a various tumors. Chordoma, a 
rare primary malignancy of the axial skeleton, is a locally aggressive and highly recurrent tumor 
associated with significant morbidity and mortality. Surgery and radiation have remained the 
mainstays of treatment for the past few decades largely due to ineffective cytotoxic 
chemotherapy and the lack of first-line small molecule-based targeted therapeutics. With the 
resurgence of interest in immunotherapeutics for cancer, the work in this thesis makes early 
breakthroughs in our understanding of the role of the immune system in chordoma pathogenesis 
at a pivotal time. To our knowledge, we are the first to report lymphocytic infiltration in a high 
percentage of resected human chordoma tumors. Intratumoral lymphocytes have been shown to 
be associated with improved prognoses in a number of other malignancies. We also are the first 
to describe HLA class I antigen defects in a significant number of chordoma tumors. Nearly 80% 
of tumors displayed defective expression of at least one component of the HLA class I antigen. 
Taken together, these findings support the possibility that patients mount an immune response 
against their tumor, and that these intratumoral lymphocytes impose selective pressure on 
malignant cells, leading to the clonal expansion of cells with the ability to evade 
immunosurveillance through defective tumor antigen presentation. These immune mechanisms 
involved in chordoma pathogenesis are critical for prognostication, tumor phenotyping, directing 
appropriate immunotherapy to the right patient cohorts, optimally selecting patients for various 
treatment regimens, and stimulating further research into the interplay between the host immune 
system and chordoma.  
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Figure 1.  HLA class I APM preparing TA peptides for presentation to T cells at the cell 
surface. The proteasome generates peptides of appropriate length (8-10 amino acids) that are 
transported to the ER by the transporter TAP. In the ER, peptides are loaded on the HLA class I 
heavy chain-β2m complexes. The tri-molecular complex is then transported through the Golgi 
secretory pathway to the cell surface for presentation of TA-derived peptides to cognate T cells. 
APM, antigen processing machinery; β2m, beta-2-microglobulin light chain; CTL, cytotoxic T 
lymphocyte; ER, endoplasmic reticulum; HLA, human leukocyte antigen; TA, tumor antigen. 
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Figure 2.  Lymphocytic infiltration in chordoma. H&E staining of human chordoma tissue 
detailing the pathologic distribution of lymphocytes within the tumor microenvironment (left) in 
comparison to human chordoma tissue without lymphocytic infiltration (right). The more 
common pattern for lymphocytic infiltration was within the fibrous septae. H&E, hematoxylin & 
eosin.  
 





Figure 3.  IHC analysis of tumor-infiltrating lymphocytes in human chordoma tumors. 
Both CD4 and CD8 T lymphocytes were noted chordoma specimens. Low-power images taken 
at 200x total magnification. High-power images taken at 400x total magnification. Interpretation 
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Figure 4.  IHC analysis of HLA class I antigen component defects in human chordoma 
tumors. Human chordoma tissue sections were stained with monoclonal antibodies directed 
against the HLA class I heavy chain isoforms (HLA-A, HLA-B/C) and the light chain (β2m). 
Staining was scored by both intensity (strongly positive, weakly positive, negative) and 
percentage of tumor cells staining positive. Scoring was performed independently by at least 2 
investigators and was confirmed independently by a senior bone and soft tissue pathologist. β2m, 
beta-2-microglobulin light chain; HLA, human leukocyte antigen. 
HLA-A 
HLA-B/C 
Weakly positive Negative 
2m 
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Figure 5.  Frequency of HLA class I antigen defects in 24 human chordoma tumors. HLA 
class I antigen component expression was determined via IHC analysis. β2m, beta-2-
microglobulin light chain; HLA, human leukocyte antigen. 
 
